Overview

Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:
0

Participant gender:
Female

Summary

This is a randomized clinical trial to investigate the efficacy of letrozole combined with metronomic oral cyclophosphamide in elderly metastasis breast cancer patients.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Capital Medical University

Treatments:

Cyclophosphamide
Letrozole

Criteria

Inclusion Criteria:

- Histologically confirmed metastatic breast cancers patients with estrogen receptor
positive and/or progesterone receptor positive;

- Elderly women (age ≥ 65years)

- Failure or relapse from standard chemotherapy or unfit for chemotherapy

- Measurable disease per Response Evaluation Criteria in Solid Tumors(RECIST);

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

- Adequate bone marrow, liver and renal function;

- Estimated life expectancy of at least 3 months.

Exclusion Criteria:

- Serious or uncontrolled concurrent medical illness

- Uncontrolled primary and metastatic brain tumor

- History of second primary malignancies

- Having been enrolled in other clinical trials within a month